We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Proteolysis Inhibitors Fail to Halt Metastasis

By Biotechdaily staff writers
Posted on 04 Feb 2003
Researchers have found that some types of cancer cells revert to a primitive amoeboid form of movement when treated with enzyme inhibitors intended to prevent the normal proteolysis-based movement of the cells during metastasis. More...
The finding was reported in the January 20, 2003, issue of the Journal of Cell Biology.

Investigators from the University of Wuerzburg (Germany) treated fibrosarcoma and carcinoma cells with a series of inhibitors to prevent the proteolytic activity of MT1–matrix metalloproteinase (MMP), which normally allows the cancer cells to burrow through the extracellular matrix (ECM) and spread from the site of the original tumor. They found that the treated cancer cells changed shape, became rounded, and were able to squeeze through already existing gaps in the ECM by using an amoeba-like movement.

The authors concluded that to be successful in preventing metastasis, drug treatments against proteolysis-dependent movement must be supplemented with agents capable of stopping the amoeboid movement.




Related Links:
University of Wuerzburg

New
Gold Member
Automatic Hematology Analyzer
CF9600
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Total Laboratory Automation Solution
SATLARS Mini T8
New
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: An elevated neutrophil-to-lymphocyte ratio (NLR), a rato easily obtained from a routine blood count, was associated with both short- and long-term Alzheimer’s risk (photo credit: 123RF)

Routine Blood Count Ratio Linked to Future Alzheimer’s and Dementia Risk

Alzheimer’s disease and related dementias develop over years, making it difficult to identify at-risk patients before symptoms appear. Clinicians therefore need widely available laboratory markers that... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.